Chiron Corporation

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Retrieved on: 
월요일, 4월 8, 2024
Retina, Amgen, Organization, Regeneron Pharmaceuticals, Doctor of Pharmacy, Chiron Corporation, Patient, ISTA Pharmaceuticals, Bayer, Shore, AMD, Ophthalmology, Pharmaceutical industry

Dr. Han will report to Chief Executive Officer (CEO), Frederic Guerard, PharmD, and will join the Opthea Executive Management Team.

Key Points: 
  • Dr. Han will report to Chief Executive Officer (CEO), Frederic Guerard, PharmD, and will join the Opthea Executive Management Team.
  • Dr. Han brings over 20 years of experience building medical affairs programs and partnering across organizations to lead pre- and post-launch initiatives for medicines in ophthalmology and retinal disease.
  • Over the course of his career, Dr. Han has served in senior leadership positions in medical and scientific affairs at leading biopharmaceutical companies.
  • He joins Opthea from Adverum Biotechnologies, Inc. where he led the development of the Medical Affairs function.

Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

Retrieved on: 
수요일, 2월 28, 2024
CFO, Acquisition, Therapy, Accounting, Prudential Securities, FP, FP&A, Growth, Senior advisor, Stanford University, KPMG, Portola Pharmaceuticals, Alexion, University, Patient, Novartis, NASH, Chiron Corporation, UCLA, Fatty liver disease, Biology, Management

CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Mardi C. Dier has been appointed Chief Financial Officer.

Key Points: 
  • CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Mardi C. Dier has been appointed Chief Financial Officer.
  • She joined Ultragenyx from Portola Pharmaceuticals (acquired by Alexion), where she served as Chief Financial Officer for 14 years and, most recently, as Chief Business Officer and Chief Financial Officer.
  • Ms. Dier joined Madrigal on February 27, 2024, as an employee in a Senior Advisor role to the Company’s current Chief Financial Officer, Alex Howarth, and will move into the Chief Financial Officer role on March 11, 2024.
  • “As we welcome Mardi to the Madrigal team, I’d also like to thank our outgoing Chief Financial Officer Alex Howarth for his substantial contributions to the Company,” said Bill Sibold.

MBrace Therapeutics Appoints Steve Alley as Chief Scientific Officer

Retrieved on: 
화요일, 3월 5, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Pfizer, Pathogenesis, Pennsylvania State University, DMPK, Cancer, Culture, Growth, Spacecraft, ADC, Linfield University, University, Therapy, Patient, MBrace, Chiron Corporation

MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), today announced the appointment of Steve Alley, Ph.D., as chief scientific officer.

Key Points: 
  • MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), today announced the appointment of Steve Alley, Ph.D., as chief scientific officer.
  • Dr. Alley joins MBrace with over 20 years of experience at Seagen, a world-leader in ADCs that was acquired by Pfizer in 2023.
  • “We are thrilled to welcome Dr. Alley to the MBrace team.
  • Dr. Alley has exceptional expertise in ADC development, and his vision will undoubtedly help propel the progress for our discovery and clinical programs,” said Isan Chen, M.D., president and chief executive officer at MBrace Therapeutics.

Osivax Appoints Dr. Nicola Groth as Chief Medical Officer

Retrieved on: 
목요일, 1월 25, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Entrepreneurship, Chiron Corporation, MD, Influenza, Novartis, Global health, GSK, University, Diagnosis, Epidemiology, CMO, Doctor of Philosophy, Vaccine, GSK plc, Preventive healthcare

Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer.

Key Points: 
  • Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer.
  • Dr. Groth joins Osivax as the company advances the development of its lead candidate, OVX836, a best-in-class broad-spectrum influenza vaccine candidate currently being evaluated in several Phase 2 clinical trials.
  • Dr. Groth takes over from Dr. Willems, whose contribution has been instrumental in advancing Osivax’ clinical strategy.
  • Nicola Groth holds a Doctor of Medicine and a PhD in Hygiene and Preventive Medicine from the University of Siena, Italy.

Nucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific Officer

Retrieved on: 
월요일, 11월 13, 2023
Natural science, University, Genetics, Research, Senior, Therapy, Nektar Therapeutics, Biotechnology, Pain management, Genomics, Chiron Corporation, Molecular biology, Genome, Nektar, Drug discovery, San Francisco Bay Area, Doctor of Philosophy, Amgen, Pharmaceutical industry, Management

Oxford, UK, 13 November 2023 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company decoding the dark matter of the human genome for translational medicine, today announces the appointment of Dr Stephen Harrison as Chief Scientific Officer, effective immediately.

Key Points: 
  • Oxford, UK, 13 November 2023 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company decoding the dark matter of the human genome for translational medicine, today announces the appointment of Dr Stephen Harrison as Chief Scientific Officer, effective immediately.
  • Prior to joining Nucleome, Dr Harrison held executive leadership positions at several biotechnology companies in the San Francisco Bay Area.
  • Most recently, he served as Chief Scientific Officer at Engine Biosciences, building and leading a team focused on functional genomics and machine learning-led target and drug discovery.
  • Dr Danuta Jeziorska, Chief Executive Officer and Founder of Nucleome, commented: “Steve has an outstanding track record in accelerated drug discovery and development across multiple therapeutic areas and innovative technologies.

Peptone Expands Leadership Team with Key Executive Hires

Retrieved on: 
목요일, 9월 28, 2023
University of Oxford, DNA, Laboratory, Specialization, Drug development, University, Therapy, Senior, Intrinsically disordered proteins, Chiron Corporation, Drug discovery, CSO, Head, Abbott Laboratories, Nuffield Department of Population Health, Gritstone bio, Inflammation, Antibody, Doctor of Philosophy, AstraZeneca, Drug design, Internally displaced person, Messenger, McKinsey & Company, Neuroscience, Cryogenic electron microscopy, Protein, MD, Biophysics, Chairperson, Jazz Pharmaceuticals, Biology, Growth, Imperial College London, Rucaparib, Exosome, DNA methylation, Research, Clovis Oncology, Health, A-DNA, SVP, PARP, Somerville College, Oxford, Disease, Management, Pharmaceutical industry, Medicine, Peptide, Immunology

LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors. Patrik Foerch, PhD, has been appointed Chief Scientific Officer; David Lowe, PhD, joins as Senior Vice President of Protein Therapeutics; and Benjamin Owens, PhD, previously Chief Strategy Officer, has transitioned to the role of Chief Business Officer and will join Peptone's Board of Directors as Executive Director. Andrew Allen, MD, PhD, co-founder, President and CEO of Gritstone bio, has been appointed Board Chair.

Key Points: 
  • LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors.
  • "I'm excited to join this incredible team to chart new territory with potential to open therapeutic opportunities across a broad range of diseases."
  • Prior to joining Peptone, he served as Vice President of Research at Evox Therapeutics, a company focused on the development of exosomes as therapeutics.
  • He has also held clinical development leadership positions at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company.

Peptone Expands Leadership Team with Key Executive Hires

Retrieved on: 
목요일, 9월 28, 2023
University of Oxford, DNA, Laboratory, Specialization, Drug development, University, Therapy, Senior, Intrinsically disordered proteins, Chiron Corporation, Drug discovery, CSO, Head, Abbott Laboratories, Nuffield Department of Population Health, Gritstone bio, Inflammation, Antibody, Doctor of Philosophy, AstraZeneca, Drug design, Internally displaced person, Messenger, McKinsey & Company, Neuroscience, Cryogenic electron microscopy, Protein, MD, Biophysics, Chairperson, Jazz Pharmaceuticals, Biology, Growth, Imperial College London, Rucaparib, Exosome, DNA methylation, Research, Clovis Oncology, Health, A-DNA, SVP, PARP, Somerville College, Oxford, Disease, Management, Pharmaceutical industry, Medicine, Peptide, Immunology

LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors. Patrik Foerch, PhD, has been appointed Chief Scientific Officer; David Lowe, PhD, joins as Senior Vice President of Protein Therapeutics; and Benjamin Owens, PhD, previously Chief Strategy Officer, has transitioned to the role of Chief Business Officer and will join Peptone's Board of Directors as Executive Director. Andrew Allen, MD, PhD, co-founder, President and CEO of Gritstone bio, has been appointed Board Chair.

Key Points: 
  • LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors.
  • "I'm excited to join this incredible team to chart new territory with potential to open therapeutic opportunities across a broad range of diseases."
  • Prior to joining Peptone, he served as Vice President of Research at Evox Therapeutics, a company focused on the development of exosomes as therapeutics.
  • He has also held clinical development leadership positions at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company.

Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development

Retrieved on: 
목요일, 9월 21, 2023
GMP, Hoffman, Amgen, Senior, Partner, Bayer, MBA, Georgetown University, Chemistry, Adenosine, Patient, Blue jay, Leukemia, Columbia University, Business development, BS, Cancer and Leukemia Group B, Infection, Leukemia & Lymphoma Society, MS, Corporation, Apple tree, Five-prime cap, Liver, NNRTI, Technology transfer, Roche, Business, Gilead Sciences, Amicus, Providence College, CMO, AbbVie, SAN, A2A, Amicus Therapeutics, Therapy, HBV, Catalant, SQZ, Model Business Corporation Act, HIV, Chiron Corporation, Hepatology, Oppenheimer, CMC, NDA, Hepatitis C, IND World's Fair Line, HCV, Management, Pharmaceutical industry, Genentech, ImmunityBio COVID-19 vaccine, Biotechnology, Searle

He will be a member of Bluejay’s Executive team, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics.

Key Points: 
  • He will be a member of Bluejay’s Executive team, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics.
  • “I am delighted to welcome Chris to the senior leadership team at Bluejay”, stated Mrs. Chu.
  • “Chris has an outstanding track record in business & corporate development with both public and private biotech and pharma companies.
  • Before joining Bluejay, he served as VP, Business & Corporate development at LEXEO Therapeutics, where he led all business development, strategic transactions and played a significant role in the company’s capital raising activities.

Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development

Retrieved on: 
금요일, 7월 28, 2023
GSK, Research and development, Drug development, Therapy, Senior, Chiron Corporation, Spectrum Pharmaceuticals, Skin cancer, Development, Baxter International, Knowledge, RNA interference, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Pfizer

and SUZHOU, China, July 27, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that Dr. Francois Lebel, M.D., an experienced biopharmaceutical industry executive, has been appointed as Senior Vice President for preclinical and clinical development of the Group.

Key Points: 
  • and SUZHOU, China, July 27, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that Dr. Francois Lebel, M.D., an experienced biopharmaceutical industry executive, has been appointed as Senior Vice President for preclinical and clinical development of the Group.
  • "With Dr. Lebel's indepth knowledge and experience in novel drug product marketing approvals, Dr. Lebel's addition to Sirnaomics' senior leadership will greatly enhance our capability to advance its therapeutic candidates through the late-stage product development.
  • Dr. Lebel is a strategic leader with broad drug development experience including immunooncology and nucleic acid therapeutics.
  • After joining Sirnaomics as Senior Vice President for preclinical and clinical development, Dr. Lebel will take a leading role in the Group's late-stage product development of the innovative RNAi drug candidates.

Veralox Names Jonathan Mow as Chief Executive Officer as the Company Advances Development of First-in-Class Therapies for Immune-Mediated Diseases in Conjunction with Financing

Retrieved on: 
화요일, 6월 20, 2023
Gilead Sciences, University, Chiron Corporation, Marketing, Biotechnology, Business, Research, Bristol Myers Squibb, HIT, Sale, Acquisition, Berkeley, Disease, University of California, Berkeley, Amylin Pharmaceuticals, Mortality, Therapy, Heparin, Pharmaceutical industry, Vaccine

FREDERICK, Md., June 20, 2023 (GLOBE NEWSWIRE) -- Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway to address some of medicine’s most persistent and serious immune-mediated diseases, today announced the appointment of Jonathan Mow as the company’s new chief executive officer.

Key Points: 
  • In conjunction with the financing, the company welcomes Peter Young of Pappas Capital as a director and Meg Wood of NYBC Ventures as an observer.
  • “VLX-1005 has great promise to revolutionize the treatment of HIT and other immune-mediated diseases,” Mr. Young said.
  • Mr. Mow has also held positions in marketing, marketing research and sales at Bristol-Myers Squibb, Wyeth/Lederle International and Syntex Laboratories.
  • in mechanical engineering from University of California at Berkeley and M.B.A. from Carnegie Mellon University’s Tepper School of Business.